OLMEDA BIOSCIENCES LLC

Medtech · Private

Proteomic biomarker assay using aqueous humor to predict uveal melanoma metastasis risk

Grants
$451K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a Novel Aqueous Humor-Based Multiplex Assay for Uveal Melanoma Metastatic Risk Prediction$396,161
Federal grantDepartment of Health and Human Services · Phase I · Development of a Novel Aqueous Humor-Based Multiplex Assay for Uveal Melanoma Metastatic Risk Prediction$55,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2034SONOVANCE, INC.——
2035ENDOTAT BIOTECHNOLOGIES LLC——
2036EMBIOSYS INC.——
2037OLMEDA BIOSCIENCES LLC——
2038AIMLOXY LLC——
2039PERSISTENCE THERAPEUTICS, INC.——
2040EYESCREEN, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.